Category: Worming
Royal Mail Tracked 24 (Signed For)
Royal Mail Special Delivery Guaranteed by 1pm
| Category | POM-VPS |
| Temperature | Ambient |
| MA/VM/EU No: | 42058/4029 |
| Species |
|
| VMD Link | https://www.vmd.defra.gov.uk/ProductInformationDatabase/product/A007168 |
| NOAH Link | https://www.noahcompendium.co.uk/?id=-456834 |
| Dosage | Dosage is 0.5 ml/10 kg bodyweight to give 1 mg moxidectin/kg bodyweight. The 50 ml vial stoppers must not be broached more than 10 times. Use automatic syringe equipment for the 200 ml and 500 ml vials. Use the following table as a guide: No of doses per pack Weight of sheep kg Dose ml 50 ml 200 ml 500 ml 20 1.0 50 200 500 30 1.5 33 133 333 40 2.0 25 100 250 50 2.5 20 80 200 60 3.0 17 67 167 70 3.5 14 57 143 80 4.0 13 50 125 90 4.5 11 44 111 100 5.0 10 40 100 To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device should be checked. If animals are to be treated collectively rather than individually, they should be grouped according to their bodyweight and dosed accordingly, in order to avoid under- or overdosing. The injection should be administered as a single subcutaneous injection at the base of the ear using an 18 gauge, 25 mm hypodermic needle. With the animal's head under control, the formulation should be administered about 2cm caudal from the anterior (rostral) edge of the pinna at the base of the ear. The skin at the base of the selected ear should be pinched and the product injected into the subcutaneous tissue. Following subcutaneous administration, the needle should be withdrawn from the skin as pressure is applied with the thumb at the point of insertion for several seconds. If leakage occurs then pressure should be applied for several additional seconds. Diagram: Ear injection technique Description:... |
| Withdrawals | Do not use in sheep less than 15 kg bodyweight. Do not inject the product by the intravascular route. Intravascular injection may result in ataxia, paralysis, convulsions, collapse and death. See “Dosage and administration” section above. Do not use in cases of hypersensitivity to the active substance or to any excipients. Swelling and inflammation may be found at the injection site in some animals. The swelling generally disappears within 7 days of treatment and generally resolves without any medical treatment. In rare cases (more than 1 but less than 10 animals in 10,000 animals treated), adverse reactions such as transitory salivation, depression, drowsiness and ataxia might occur. No particular treatment is required; these symptoms usually disappear within 24 to 48 hours. There is no specific antidote. Signs of overdoses have not been seen at 3 and 5 times the recommended dose. However, if they do occur they should be consistent with the mode of action of moxidectin and would be manifested as transient salivation, depression, drowsiness and ataxia 24 to 36 hours post-treatment. The signs would usually disappear within 36 to 72 hours without treatment. There is no specific antidote. CYDECTIN 20 mg/ml LA for Sheep has been formulated specifically for subcutaneous injection in the base of the ear of sheep and must not be given by any other route of administration or to any other species. Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: - Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. - Underdosing, which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration of the dosing device (if any). Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used. Resistance to macrocyclic lactones has been reported in Teladorsagia in sheep in a number of countries. In 2008, throughout Europe, moxidectin resistance is very rare; it has been reported in a single case involving a levamisole-, benzimidazole and ivermectin-resistant strain of Teladorsagia circumcincta. Therefore the use of moxidectin should be based on local (regional, farm) epidemiological information about susceptibility of nematodes, local history of treatments and recommendations on how to use the product under sustainable conditions to limit further selection for resistance to anthelmintics. These precautions are especially important when moxidectin is being used to control resistant strains. Withdrawal period Meat and offal: 104 days. Milk: Not permitted for use in dairy sheep, at any stage of life. The withdrawal period is based solely on a single injection at the base of the ear. Operator warnings Avoid direct contact with skin and eyes. Wash hands after use. Do not smoke, drink or eat while handling the product. Take care to avoid self-injection. If this occurs, it is unlikely that any product related symptoms will be observed. Advice to Medical Practitioners in case of accidental self-injection: Treat symptomatically. Other precautions regarding impact on the environment Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic (PBT) substance; therefore, exposure of the environment to moxidectin must be limited to the extent possible. Treatments should be administered only when necessary and should be based on faecal egg counts or evaluation of the risk of infestation at the animal and/or herd level. Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-target organisms: •Faeces containing moxidectin excreted onto pasture by treated animals may temporarily reduce the abundance of dung feeding organisms. Following treatment of sheep with the product, levels of moxidectin that are potentially toxic to dung fly species may be excreted over a period of more than 4 weeks and may decrease dung fly abundance during that period. It has been established in laboratory tests that moxidectin may temporarily affect dung beetle reproduction; however, studies with incurred residues indicate no long-term effects. Nevertheless, in case of repeated treatments with moxidectin (as with products of the same anthelmintic class) it is advisable not to treat animals every time on the same pasture to allow dung fauna populations to recover. •Moxidectin is inherently toxic to aquatic organisms including fish. The product should be used only according to the label instructions. Based on the excretion profile of moxidectin when administered as the injectable formulation to sheep, treated animals should not have access to watercourses during the first 11 days after treatment. |
Animally Vet Supplies is the trading name of Veterinary Meds Online Ltd.
Company No. 12665548 | VMR No. 7386568 | Copyright 2022© All rights Reserved
